Question explored with the scientific record
Conversation so far
- 1 What are the long term effects of taking hydroxycarbamide
- 2 What long-term side effects are seen in adults with polycythemia vera or ET?
- 3 What long-term effects are reported on blood counts and marrow health?
Answered on this page ↓
What long-term effects are reported on blood counts and marrow health?
The short version: the evidence retrieved does not answer your question about long-term blood counts and marrow health in polycythemia vera or essential thrombocythemia.
The retrieved studies describe disease course and treatment effects, but none measure long-term changes in peripheral blood counts or marrow grade over time in these patients. The closest data comes from a 15-year observational study of 358 patients with ET and PV [15]. It reports that low hemoglobin and high white cell count predict transformation to myelofibrosis or leukemia in ET, and that splenic enlargement and increased reticulin predict transformation in PV [15]. That is prognostic, not a longitudinal measurement of marrow grade.
The Korean registry study of 7,454 MPN patients shows the real long-term risks: ET has an 8-year cumulative incidence of 3.6% for acute myeloid leukemia and 2.8% for myelofibrosis; PV has 1.7% and 1.2% respectively [16]. These are disease outcomes, not treatment effects. No study in this evidence set compared treated versus untreated patients for marrow changes.
| Condition | 8-yr AML risk | 8-yr myelofibrosis risk |
|---|---|---|
| Essential thrombocythemia | 3.6% | 2.8% |
| Polycythemia vera | 1.7% | 1.2% |
The JAK2 V617F mutation roughly doubles thrombosis risk (OR 1.88) and strongly predicts progression to PV (OR 7.67) [18]. But none of this tells you what hydroxyurea or other cytoreductive drugs do to marrow over decades. That question remains unstudied in this evidence.
My call: the evidence retrieved does not address long-term treatment effects on blood counts or marrow morphology. Confidence: not clear.
Sources used 19
-
Hematological Toxicity of 1-β-D-Arabinofuranosylcytosine, and its Prevention by Deoxycytidine, in the Mouse
In mice, cytarabine (ara-C) caused rapid but transient hematological toxicity including leukopenia, thrombocytopenia, and erythroid suppression, which was largely prevented by concurrent deoxycytidine (CdR) except for a delayed platelet recovery.
DOI: 10.1159/000220712 -
Multivessel coronary thrombosis treated with abciximab (reopro®) in a patient with essential thrombocythemia
A case report of a 50-year-old Mexican man with essential thrombocythemia presenting with multivessel coronary thrombosis and acute myocardial infarction who was treated with aspirin, heparin, ticlopidine, hydroxyurea, and abciximab (ReoPro), resulting in rapid thrombus resoluti…
DOI: 10.1002/CLC.4960210218 -
Retinal Vein Thrombosis as the Presenting Symptom of Essential Thrombocythemia
This case report describes the first known instance of retinal vein thrombosis presenting as a symptom of essential thrombocythemia in a young female patient, highlighting the need for hematologic evaluation in similar cases.
DOI: 10.1097/00000441-200503000-00005 -
Ultrastructural Analysis of Platelets and Megakaryocytes from a Dog with Probable Essential Thrombocythemia
This study presents an ultrastructural analysis of platelets and megakaryocytes from a dog diagnosed with essential thrombocythemia, revealing significant abnormalities in cell morphology and maturation compared to control dogs.
DOI: 10.1177/030098588902600401 -
Inhibition of cell‐mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T‐cell lymphoma
In patients presenting with essential thrombocythemia, the study evaluated whether routine blood tests (Hb, WBC, LDH) can help distinguish early primary myelofibrosis from true ET, proposing a practical algorithm that classifies about half of cases without bone marrow biopsy.
DOI: 10.1002/ajh.22231 -
Multiple Granulocytic Sarcomas in Essential Thrombocythemia
This case report describes a rare instance of multiple granulocytic sarcomas developing in a patient with essential thrombocythemia, without transformation to overt leukemia, highlighting the potential role of chromosomal abnormalities in this progression.
DOI: 10.1532/IJH97.06081 -
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
This study investigates the mechanisms behind aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia and demonstrates that adjusting the dosing interval of aspirin can significantly enhance its antiplatelet effects.
DOI: 10.1182/blood-2011-06-359224 -
Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works
This study presents two cases of livedo racemosa in patients with essential thrombocythemia, highlighting the importance of recognizing cutaneous manifestations for early diagnosis and treatment to prevent severe thromboembolic events.
DOI: 10.1111/1346-8138.13561 -
Clinical course of essential thrombocythemia in 147 cases
This study retrospectively analyzes the clinical course, treatment, and outcomes of 147 patients with essential thrombocythemia, highlighting the prevalence of thrombotic events and the effectiveness of cytoreductive therapy.
DOI: 10.1002/1097-0142(19900801)66:3<549::aid-cncr2820660324>3.0.co;2-6 -
Trisomy 1q in a case of essential thrombocythemia with long survival
This study presents a case of a 75-year-old woman with essential thrombocythemia who exhibited trisomy 1q, highlighting the potential implications of chromosomal abnormalities in myeloproliferative disorders.
DOI: 10.1016/0165-4608(87)90177-4 -
Blood consult: resistant and progressive essential thrombocythemia
This case study discusses the management of a 58-year-old man with resistant and progressive essential thrombocythemia, highlighting the challenges of treatment resistance and the potential for JAK2 inhibitors and stem cell transplantation.
DOI: 10.1182/blood-2011-01-327213 -
Acute coronary syndrome associated with essential thrombocythemia
This study presents a case of acute coronary syndrome in a 47-year-old woman with essential thrombocythemia, highlighting the challenges in management and the successful use of percutaneous coronary intervention combined with platelet-lowering therapy.
DOI: 10.1016/j.jjcc.2009.03.001 -
Spinal surgery in a patient with essential thrombocythemia resulting in leg paraplegia: a case report
This case report describes an 82-year-old man with essential thrombocythemia who underwent spinal surgery for lumbar canal stenosis, resulting in postoperative complications including leg paraplegia and highlights the need for improved perioperative management guidelines for suc…
DOI: 10.1016/j.spinee.2013.06.018 -
Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis
This study presents a logistic regression algorithm that significantly improves the differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis, achieving a diagnostic accuracy of 92% compared to 52% when relying solely on hematocrit levels.
DOI: 10.1002/ajh.2830250209 -
The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera
This study investigates the impact of peripheral blood values and bone marrow findings on the prognosis of patients with essential thrombocythemia and polycythemia vera, revealing significant differences in survival and transformation risks between the two conditions.
DOI: 10.1111/j.1600-0609.2010.01548.x -
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms
South Korean patients with BCR-ABL1-negative myeloproliferative neoplasms have roughly a twofold higher risk of developing second primary solid tumors than the general population, with primary myelofibrosis showing especially high risk of leukemic transformation and additional c…
DOI: 10.1182/bloodadvances.2019000655 -
Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation
CRISPR/Cas9-edited Jak2-R1063H knock-in mice and human MPN patient data reveal that a germline Jak2-R1063H mutation drives platelet-biased direct MkP differentiation, accelerates hematopoietic stem cell aging, increases thrombosis risk, and cooperates with leukemogenic events to…
DOI: 10.1038/s41375-025-02737-w -
Is JAK2 V617F mutation more than a diagnostic index?
A systematic review and meta-analysis of essential thrombocythemia shows that JAK2 V617F mutation is associated with higher risk of thrombosis and progression to polycythemia vera, with leukocytosis partially mediating the thrombotic risk.
DOI: 10.1016/j.leukres.2008.06.006 -
Myeloproliferative disorders in older people
This article provides a comprehensive clinical review of the four major myeloproliferative disorders in older adults (polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia), outlining their epidemiology, molecular pathogenesis (JAK2 an…
DOI: 10.1017/S0959259811000256